Company Overview
About Dyno Therapeutics
Dyno Therapeutics is a Cambridge, Massachusetts-based gene therapy biotechnology company founded in 2018 by George Church (Harvard), Eric Kelsic, and Sam Sinai. The company's core insight is that the adeno-associated virus (AAV) — the dominant vector for approved gene therapies — has enormous untapped diversity in its capsid protein sequences, and that AI can be used to explore this diversity space far more efficiently than directed evolution or rational design alone. Dyno's platform generates hundreds of thousands of synthetic AAV capsid variants, characterizes their properties in high-throughput cell and animal assays, and uses machine learning to learn the sequence-function relationships that determine tissue targeting, manufacturing yield, and immune evasion.
Business Model & Competitive Advantage
The company raised a $100M Series B from investors including Andreessen Horowitz Bio + Health, GV (Google Ventures), Alexandria Venture Investments, and others. Dyno has established strategic partnerships with AstraZeneca (cardiovascular and rare disease programs) and Sarepta Therapeutics (Duchenne muscular dystrophy programs), providing validation of its technology from major pharma partners. These partnerships are structured to give Dyno milestone payments and royalties on any capsids used in approved therapies.
Competitive Landscape 2025–2026
Dyno's approach directly addresses the most significant limitations of current gene therapies: first-generation AAV capsids (AAV9, AAVrh10, etc.) have pre-existing immunity in a large fraction of the population (limiting patient eligibility), insufficient tissue specificity (causing off-target expression), and manufacturing challenges at commercial scale. Dyno's AI-engineered capsids are designed to overcome these limitations simultaneously — enabling broader patient eligibility, better therapeutic profiles, and more scalable production processes.
Key Differentiators
Emerging Innovator
Dyno Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Dyno Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Dyno Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Dyno Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Dyno Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →